ClinicalTrials.gg
CompletedNCT06350838Updated Apr 5, 2024

Clinical Study to Investigate the Safety and Tolerance of Therapeutic BCG in Postoperative Adjuvant Therapy in Subjects With Moderate to High-risk Non-muscular Invasive Bladder Cancer (NMIBC)

A Phase 1 interventional study of BCG for Therapeutic Use in Non-muscular Invasive Bladder Cancer, sponsored by Chengdu CoenBiotech Co., Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2024-04-05.

Sponsored by Chengdu CoenBiotech Co., Ltd · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 2 months after the study started (first participant enrolled Nov 2022, registered Jan 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing BCG Vaccine in Urinary Bladder Neoplasms — 3 open to participants now, 8 under way, 4 of them phase 3. BCG Vaccine · Urinary Bladder Neoplasms.

Enrollment
18th of 20
10 · median 112
Started
2022
the only one that year
Phase 1
4 of 20
none open now
Registered
17th of 20
by date
Lead sponsor
2 of 20
Chengdu CoenBiotech Co., Ltd

Among the 20 studies testing BCG Vaccine in Urinary Bladder Neoplasms, this one is the 18th largest by enrollment, is the only one that started in 2022, is one of 4 in phase 1, and was the 17th registered.

Urinary Bladder Neoplasms

1,800 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.

Browse Urinary Bladder Neoplasms studies →

Open to participants now

3 of the 20 studies testing BCG Vaccine in Urinary Bladder Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About BCG Vaccine

BCG Vaccine: first FDA approval 1989 (N/A). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 336 Urinary Bladder Neoplasms studies recruiting now, 256 (76%) set no upper age limit and 22 (7%) stop at 75 or younger; 22 take children under 18; 21 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing BCG Vaccine in Urinary Bladder Neoplasms, or all of them as a file.
02

Study summary

Phase I clinical study to investigate the safety and tolerance of therapeutic BCG in postoperative adjuvant therapy in subjects with moderate to high-risk non-muscular invasive bladder cancer (NMIBC)

Read the detailed description

The purpose of this study was to evaluate the safety and tolerance, pharmacokinetic characteristics, ablative status, and immune response characteristics of the therapeutic BCG in postoperative adjuvant therapy in subjects with moderate and high-risk non-invasive bladder cancer (NMIBC).

The study consisted of three phases: screening period, administration observation period and safety follow-up period. subjects will be treated with 120 mg BCG.

03

Conditions studied

  • Non-muscular Invasive Bladder Cancer

Keywords

  • Non-muscular invasive bladder cancer
  • bladder cancer
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects were ≥18 years old and ≤85 years old, male or female;
  • Subjects with non-myoinvasive bladder uroepithelial carcinoma initially diagnosed by histology [T1, Ta, or Tis stage (carcinoma in situ)] and assessed as moderate to high-risk non-myoinvasive bladder uroepithelial carcinoma requiring BCG injection therapy according to the Guidelines for Bladder Cancer Diagnosis and Treatment (2022 edition); (Subjects considered for secondary resection may be included in the study after completion of secondary resection and pathology results confirm moderate or high risk non-myoinvasive bladder cancer);
  • score: 0-2;
  • Clinical laboratory tests meet the following characteristics:

    1. Blood routine: no hematopoietic growth factor or transfusion support was used within 14 days prior to enrollment, including: absolute neutrophil value (ANC) ≥1500/mm3 or ≥1.5×109/L; ≥100000/mm3 or 100×109/L; ≥9 g/dL.
    2. Liver function: total serum ≤1.5× (ULN), total serum bilirubin \<3×ULN in subjects with Gilbert syndrome, aspartate and (AST and ALT) ≤2.5×ULN.
    3. Renal function: defined as ≥45 to 50 mL/min as estimated by the Cockcroft Gault formula.
    4. Coagulation function: (APTT) ≤1.5×ULN, International Normalized ratio (INR) ≤1.5×ULN
  • The subjects voluntarily joined the study, signed the , had good compliance, and cooperated with follow-up.

Exclusion criteria

Exclusion Criteria:

  • Any of the following:

    1. Patients who are using drugs, hormone drugs, or radiation therapy that the investigator has determined to be likely to cause systemic BCG disease reactions (patients who hormone injections for thyroid/adrenal resection may be included);
    2. Allergic to BCG vaccine or BCG products;
    3. Have active TB changes or are receiving anti-TB therapy;
    4. Known or suspected intraoperative perforation of the bladder; e Serious gross hematuria before administration was judged by the investigator, and the surgical wound was suspected to have not healed.

    f. The evaluators were judged to be associated with cystitis, or had previously received other bladder perfusion drugs, and were expected to have severe bladder irritation.

    f. Patients with a history of severe adverse reactions to BCG (BCG) sepsis or systemic infection; g. Complete bladder incontinence, defined as the use of six or more pads in a 24-hour period; h. Complete bladder incontinence, defined as the use of six or more pads in a 24-hour period;

  • Combined with other genitourinary tumors or of other organs;
  • Accompanied by serious diseases of cardiovascular and cerebrovascular, lung, liver, kidney and other important organs, or severe hypertension or diabetes that researchers judge can not be controlled clinically;
  • Patients suffering from acute infectious diseases at the time of screening;
  • Evidence of Myoinvasive locally advanced or urothelial carcinoma, or extrinsic non-Myoinvasive urothelial metastasized cell carcinoma, as determined by the investigator;
  • Study participants who had received chemotherapy, radiation therapy, or anti-tumor immunotherapy within 4 weeks prior to treatment (except for immediate postoperative bladder infusion chemotherapy);
  • Pregnant or lactating women;
  • Subjects who are unable to use effective during the trial period and within 3 months after the last dose;
  • Participants who had participated in clinical trials of other therapeutic drugs within 1 month prior to enrollment;
  • Known opioid or alcohol dependence;
  • (HIV) antibody, syphilis specific antibody positive, acute or chronic active (hepatitis B surface antigen (HBsAg) positive, and peripheral blood hepatitis B copy number ≥103/mL), virus (HCV) antibody positive (HCV copy number ≥10/mL);
  • Patients with mental disorders or poor compliance as judged by the investigator;
  • Any conditions that the investigator believes may increase risk to the subject or interfere with the execution of the clinical trial.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Medium/high-risk non-muscle invasive bladder cancer (NMIBC)

    Medium/high-risk NMIBC (Ta, T1 or Tis) suitable for intravesical BCG treatment.Three phases included: screening period (28 days before the first dose), observation period (6 weeks) and safety follow-up period (7 days after the last dose).

    Drug: BCG for Therapeutic Use

Interventions

  • Take 120 mg BCG for treatment, dissolved in 40 \~ 50 mL normal saline, bladder perfusion through catheter. The injection was performed once a week for 6 consecutive times.

    Also known as: BCG

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events(TEAE) and serious Treatment-Emergent Adverse Events;

    Probability of AE and SAE after administration.

    Time frame: 6 weeks

  2. Effects on clinical laboratory tests index of blood biochemistry, such as the concentration of alanine aminotransferase (ALT).

    Probability of abnormal laboratory parameters of blood biochemistry compared with baseline,such as the concentration of alanine aminotransferase (ALT).

    Time frame: 6 weeks

  3. Effects on clinical laboratory tests index of blood routine, such as white blood cell count, red blood cell count, platelet count.

    Probability of abnormal laboratory parameters of blood routine compared with baseline, such as white blood cell count, red blood cell count, platelet count.

    Time frame: 6 weeks

  4. Effects on clinical laboratory tests index of coagulation function, such as activated partial thromboplastin time (APTT).

    Probability of abnormal laboratory parameters of coagulation function compared with baseline,such as activated partial thromboplastin time (APTT).

    Time frame: 6 weeks

  5. Effects on clinical laboratory tests index of urine routine, such as white urine albumin count, urine red blood cell count.

    Probability of abnormal laboratory parameters of urine routine compared with baseline,such as urine albumin count, urine red blood cell count.

    Time frame: 6 weeks

  6. Effects on vital signs,such as temperature.

    Probability of abnormal laboratory parameters of vital signs compared with baseline,such as temperature(℃).

    Time frame: 6 weeks

  7. Effects on P wave, QRS complex, QT interval and so on by 12-lead electrocardiogram.

    Probability of abnormal laboratory parameters compared with baseline, including P wave, QRS complex, QT interval and so on by 12-lead electrocardiogram.

    Time frame: 6 weeks

  8. Effects on the periodic activity of echocardiography,such as the heart wall recorded as the relationship curve between the corresponding activity and time of each structure.

    Probability of abnormal laboratory parameters of echocardiography compared with baseline,such as the heart wall recorded as the relationship curve between the corresponding activity and time of each structure.

    Time frame: 6 weeks

  9. Effects on physical examination, refers to the detection and measurement of the development level of human form, structure and function.

    Probability of abnormal laboratory parameters of examination compared with baseline,such as any abnormalities in the skin.

    Time frame: 6 weeks

Secondary outcomes

  1. Exposure condition of the test drug in the blood, refer to plasma concentration of the test drug(BCG).

    Exposure to the test drug in the blood,detecting the amount and concentration of drug.

    Time frame: 6 weeks

  2. Shedding condition of the test drug in urine.

    Exposure to the test drug and in urine,detecting the amount and concentration of drug.

    Time frame: 6 weeks

  3. To investigate the immune response characteristics of therapeutic BCG in patients with moderate and high- risk non-invasive bladder cancer after surgery.

    The amount and concentration levels of IL-2, IL-6, IL-8, IL-12, IFN-γ, and TNF in urine.

    Time frame: 6 weeks

07

Study locations

1 site
  • Hunan Cancer Hospital
    Changsha, Hunan 415000, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2022 to primary completion in Feb 2023, 3 months.

Of 80 industry-sponsored phase 1 interventional studies under Urinary Bladder Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's 3 months is below that.

Counting every sponsor, half of 145 studies reached it within 43 months; a quarter within 29 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2024
First posted
Apr 5, 2024
StartActual
Nov 11, 2022
Primary completionActual
Feb 13, 2023
CompletionActual
Feb 13, 2023
Last update
Apr 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06350838
Lead sponsor
Chengdu CoenBiotech Co., Ltd
Collaborators
Hunan Cancer Hospital
Responsible party
Sponsor
First posted
Apr 5, 2024
Start date
Nov 11, 2022
Primary completion
Feb 13, 2023
Completion
Feb 13, 2023
Last update
Apr 5, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BCG Vaccine

Start the discussion